cone beam CT imaging, high-precision robotic treatment
couch, oncology information systems and treatment planning systems. The
compact, precise and affordable design of the Monarch250 proton therapy
system provides the most versatile proton treatment capabilities, enhancing
existing department capacity. For large multiple room proton centers, the
Monarch250 unique configuration of one-cyclotron for each room will provide
the most reliable, efficient and economical approach to proton therapy. The
Monarch250 has not been cleared for commercial distribution/clinical use by
the US Food and Drug Administration and is currently in development.
About Still River Systems
Still River Systems, based in Littleton, Massachusetts, is dedicated to
providing physicians and their patients access to high quality,
cost-effective proton therapy solutions, and to help establish this
superior treatment modality as a standard of care for patients worldwide.
Still River Systems is developing the Monarch250, an affordable, precise
and compact proton therapy system for cancer treatment. For more
information on Still River Systems and the Monarch250 Proton Therapy
System, please call 978-540-1500 or visit their website @
http://www.StillRiverSystems.com.
'/>"/>SOURCE Still River Systems Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health2.
Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health3.
Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated4.
Federal nanotech risk research plan still comes up short5.
RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner6.
Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner7.
Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market8.
Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems9.
BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery10.
Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway11.
NxStage Medical Provides Update on Medisystems Acquisition